Literature DB >> 25037123

Advances in pediatric pharmacology, therapeutics, and toxicology.

Daniel Gonzalez1, Ian M Paul2, Daniel K Benjamin3, Michael Cohen-Wolkowiez4.   

Abstract

In the United States, passage of the FDASIA legislation made BPCA and PREA permanent, no longer requiring reauthorization every 5 years. This landmark legislation also stressed the importance of performing clinical trials in neonates when appropriate. In Europe the Pediatric Regulation, which went into effect in early 2007, also provides a framework for expanding pediatric clinical research. Although much work remains, as a result of greater regulatory guidance more pediatric data are reaching product labels.

Entities:  

Keywords:  Pediatrics; Pharmacokinetics; Pharmacology; Toxicology

Mesh:

Year:  2014        PMID: 25037123      PMCID: PMC4120955          DOI: 10.1016/j.yapd.2014.03.005

Source DB:  PubMed          Journal:  Adv Pediatr        ISSN: 0065-3101


  66 in total

1.  Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study.

Authors:  Iain P Fraser; Lingling Han; Tae H Han; Chi-Chung Li; David Hreniuk; S Aubrey Stoch; John A Wagner; Steven Linder; Paul Winner
Journal:  Headache       Date:  2012-01-30       Impact factor: 5.887

2.  Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.

Authors:  Jay Purdy; Sylvie Jouve; Jean Li Yan; Ivana Balter; Nathalie Dartois; C Angel Cooper; Joan Korth-Bradley
Journal:  Clin Ther       Date:  2012-01-16       Impact factor: 3.393

3.  Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus.

Authors:  James M Chamberlain; Edmund V Capparelli; Kathleen M Brown; Cheryl W Vance; Kathleen Lillis; Prashant Mahajan; Richard Lichenstein; Rachel M Stanley; Colleen O Davis; Stephen Gordon; Jill M Baren; John N van den Anker
Journal:  J Pediatr       Date:  2011-11-01       Impact factor: 4.406

4.  Intramuscular versus intravenous therapy for prehospital status epilepticus.

Authors:  Robert Silbergleit; Valerie Durkalski; Daniel Lowenstein; Robin Conwit; Arthur Pancioli; Yuko Palesch; William Barsan
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

5.  Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial.

Authors:  Marzia Lazzerini; Stefano Martelossi; Giuseppe Magazzù; Salvatore Pellegrino; Maria Cristina Lucanto; Arrigo Barabino; Angela Calvi; Serena Arrigo; Paolo Lionetti; Monica Lorusso; Francesca Mangiantini; Massimo Fontana; Giovanna Zuin; Gabriella Palla; Giuseppe Maggiore; Matteo Bramuzzo; Maria Chiara Pellegrin; Massimo Maschio; Vincenzo Villanacci; Stefania Manenti; Giuliana Decorti; Sara De Iudicibus; Rossella Paparazzo; Marcella Montico; Alessandro Ventura
Journal:  JAMA       Date:  2013-11-27       Impact factor: 56.272

6.  Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study.

Authors:  Prasarn Manitpisitkul; Kevin Shalayda; Mike Todd; Shean S Wang; Seth Ness; Lisa Ford
Journal:  Epilepsia       Date:  2012-11-13       Impact factor: 5.864

7.  Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.

Authors:  Thomas D Walters; Mi-Ok Kim; Lee A Denson; Anne M Griffiths; Marla Dubinsky; James Markowitz; Robert Baldassano; Wallace Crandall; Joel Rosh; Marian Pfefferkorn; Anthony Otley; Melvin B Heyman; Neal LeLeiko; Susan Baker; Stephen L Guthery; Jonathan Evans; David Ziring; Richard Kellermayer; Michael Stephens; David Mack; Maria Oliva-Hemker; Ashish S Patel; Barbara Kirschner; Dedrick Moulton; Stanley Cohen; Sandra Kim; Chunyan Liu; Jonah Essers; Subra Kugathasan; Jeffrey S Hyams
Journal:  Gastroenterology       Date:  2013-10-23       Impact factor: 22.682

8.  Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit.

Authors:  Joseph F Standing; Angela Nika; Vasileios Tsagris; Ioannis Kapetanakis; Helena C Maltezou; Dimitris A Kafetzis; Maria N Tsolia
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

9.  Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide.

Authors:  Patrick J McNamara; Sandesh P Shivananda; Mohit Sahni; David Freeman; Anna Taddio
Journal:  Pediatr Crit Care Med       Date:  2013-01       Impact factor: 3.624

10.  Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants.

Authors:  Michael Cohen-Wolkowiez; Daniele Ouellet; P Brian Smith; Laura P James; Ashley Ross; Janice E Sullivan; Michele C Walsh; Arlene Zadell; Nancy Newman; Nicole R White; Angela D M Kashuba; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

View more
  1 in total

1.  A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA from 2007-2013.

Authors:  Gunter F Egger; Gerold T Wharton; Suzanne Malli; Jean Temeck; M Dianne Murphy; Paolo Tomasi
Journal:  Ther Innov Regul Sci       Date:  2016-05-13       Impact factor: 1.778

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.